NYSEAMERICAN:CLDI Calidi Biotherapeutics Q2 2026 Earnings Results & Report $0.60 -0.02 (-3.15%) Closing price 11/16/2026 04:10 PM EasternExtended Trading$0.61 +0.01 (+1.11%) As of 11/16/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Calidi Biotherapeutics reported Q2 2026 earnings on August 13, 2026. The company reported EPS of -$2.94. Research:ProfileEarnings History Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeAfter Market Closes Calidi Biotherapeutics EPS ResultsActual EPS-$2.94Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACalidi Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesSEC FilingEarnings HistoryCompany Profile Calidi Biotherapeutics Q2 2026 Earnings FAQ Did Calidi Biotherapeutics beat earnings estimates for Q2 2026? Calidi Biotherapeutics (NYSEAMERICAN:CLDI) reported earnings of -$2.94 per share for Q2 2026. The report was announced on Thursday, August 13, 2026. Calidi Biotherapeutics Earnings HeadlinesCalidi Biotherapeutics Q3 Net Loss Narrows Amid Restructuring For Cost SavingsNovember 16 at 9:34 AM | rttnews.comCalidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 13, 2026 | globenewswire.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout. | Behind the Markets (Ad)Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Stock Jumps 3.1% - Here's What HappenedNovember 7, 2026 | americanbankingnews.comCalidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine ...October 27, 2026 | finance.yahoo.comCalidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE BiofactoriesOctober 27, 2026 | globenewswire.comSee More Calidi Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Calidi Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calidi Biotherapeutics and other key companies, straight to your email. Email Address About Calidi BiotherapeuticsCalidi Biotherapeutics (NYSEAMERICAN:CLDI) is a clinical-stage biotechnology company developing cell-based therapies for cancer. Its approach uses stem cells as delivery vehicles for oncolytic viruses, which are designed to infect and destroy cancer cells and help activate the body’s immune response. The company’s programs focus on delivering these viruses to tumors, including through its SuperNova platform, which uses engineered allogeneic stem cells. Calidi’s work remains in development, and its products are investigational rather than approved treatments.View Calidi Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.